Floatz logo

Trastuzumab Deruxtecan

Metastatic Malignant Neoplasm In The Brain

Baptist Health South Floridaantibody_drug_conjugatePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
73/ 100

Competitive context

100 Active assets in the Metastatic Malignant Neoplasm In The Brain cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Iambic Therapeutics, Inc
Phase 4BB
Icotinib
Betta Pharmaceuticals Co., Ltd.
Phase 3BB
Copper Cu 64-DOTA-Trastuzumab
City of Hope Medical Center
Phase 4BB
Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3BB
Regorafenib
Neonc Technologies, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Trastuzumab Deruxtecan is also rated in:

breast carcinomaActive
BBB
Indicative · Phase 4
75 / 100
View asset →
breast cancerActive
BB
Indicative · Phase 4
66 / 100
View asset →
triple-negative breast carcinomaActive
BB
Indicative · Phase 2
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →